Objectives: Multidrug-resistant (MDR) Acinetobacter baumannii is increasing in our hospital and worldwide, raising the necessity of finding effective therapies. We aimed to evaluate the in vitro activity of tigecycline against MDR A. baumannii clones isolated before tigecycline was used in our institution.
Introduction
The emergence of multidrug-resistant (MDR) Acinetobacter baumannii clones worldwide and the high morbidity and mortality associated with infections caused by these strains present a challenge to clinicians. Carbapenems have been an effective treatment for these infections but resistance to this class is emerging, leading to the evolution of pan-resistant strains 1, 2 and to the need for new therapeutic options. Tigecycline is a novel broad-spectrum glycylcycline. Vast in vitro studies, analysing cumulatively several thousand A. baumannii isolates, show excellent inhibitory activity with low MIC 50 values of 0.5 to 2.0 mg/L and MIC 90 s of up to 2 mg/L, with percentage susceptibility ranging from 93% to 99%. 3 -6 This drug has been approved for treatment of complicated skin, skin structure and intra-abdominal infections, 7 and according to a recent report this drug is the only compound in the pipeline for treatment of MDR A. baumannii infections. 8 In our institution, MDR A. baumannii isolates cause polyclonal outbreaks. 9 The aim of this study was to assess the in vitro activity of tigecycline against a collection of MDR A. baumannii isolates in our hospital, before tigecycline was used, to provide data to guide an appropriate antimicrobial therapy for this organism.
Materials and methods
The in vitro activity of tigecycline was evaluated against 82 MDR A. baumannii clinical isolates. Isolates were collected consecutively in Tel Aviv Medical Center, a tertiary hospital, during a period of 6 months in 2003, and were isolated from wound (n ¼ 36), respiratory tract (n ¼ 32), blood (n ¼ 7), urine (n ¼ 6) and CSF (n ¼ 1 (Table 1 ). All the Etest MIC values measured in the resistance range correlated 100% with inhibition zone diameters using the disc diffusion method with tigecycline discs.
Almost all the 22 imipenem-non-susceptible isolates were also resistant to tigecycline (95%). Among imipenem-susceptible isolates, a high proportion were tigecycline-resistant (60%), but this proportion was lower than among imipenem-non-susceptible isolates (P ¼ 0.0038). These results suggest that tigecycline may be of limited clinical utility for the treatment of infections involving these pan-resistant strains.
Fifty-two of 82 (63%) of the isolates were susceptible to minocycline. Resistance to tigecycline was observed in minocycline-susceptible and -resistant isolates (Figure 1 ), although susceptibility was more common among minocycline-susceptible isolates (30.8% versus 6.7%, P ¼ 0.011). The mechanism or mechanisms of resistance to tigecycline in A. baumannii should be elucidated; our data suggest either clustering of two mechanisms of resistance or, more likely, the occurrence of different but presumably additive resistance mechanisms. A recent description of a tigecycline-non-susceptible MDR A. baumannii isolate emerging during tigecycline therapy 10 proves, at least partly, the involvement of an efflux pump mechanism as known from other 
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Gram-negative bacteria where decreased susceptibility to tigecycline correlates with increased levels of AcrAB. The high MICs of tigecycline observed in our study differ substantially from previous reports in which Acinetobacter isolates were almost uniformly susceptible to tigecycline. Even studies that tested MDR Acinetobacter isolates with high imipenem resistance rates 5, 6 found significantly lower MIC 90 s of 2 -8 mg/L; in our study with 24% resistance to imipenem the MIC 90 was 32 mg/L.
It should be pointed out that our susceptibility testing was based on the Etest method where previous studies used mostly broth-based methods. A recent study compared broth and Etest MIC testing and showed that Acinetobacter spp. indeed displayed the greatest change in tigecycline susceptibility, 11 but the MIC 90 differed only by a factor of two and thus the methodology differences in MIC testing do not explain the high MIC 90 we found.
Recently, non-susceptibility to tigecycline was reported in a single clone of MDR A. baumannii in the Chicago area. 12 This report is the first in vitro description of a high resistance rate to tigecycline in multiple clones of MDR A. baumannii. Although this phenomenon may be unique to our geographical region, with the increasing incidence of Acinetobacter infections and increasing rates of multidrug resistance, this phenomenon is worrisome and should be further investigated. 
